Mitokinin
Dr. Trempe is an Associate Professor in the department of Pharmacology at McGill University. He has been a pioneer in PINK1 / Parkin biology, being the first to elucidate the crystal structure of Parkin (2013) and the discoverer of the mechanism by which PINK1 autophosphorylation drives ubiquitin recognition. Dr. Trempe contributes his considerable expertise in structural biology in general and the PINK1/Parkin pathway in particular to the Company as a member of Mitokinin’s Scientific Advisory Board.
Dr. Trempe obtained his doctoral degree from the University of Oxford in 2007. He pursued postdoctoral training at McGill University and the Montreal Neurological Institute, Canada, and became an assistant professor at McGill University in 2013.
This person is not in the org chart
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.